{"id":"NCT00216476","sponsor":"Janssen-Cilag International NV","briefTitle":"A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder","officialTitle":"CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-10","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2005-09-22","resultsPosted":"2010-08-10","lastUpdate":"2014-04-16"},"enrollment":753,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Psychotic Disorders"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":[]},{"type":"DRUG","name":"Risperidone Long Acting Injectable (LAI)","otherNames":[]},{"type":"DRUG","name":"Quetiapine","otherNames":[]}],"arms":[{"label":"001","type":"EXPERIMENTAL"},{"label":"002","type":"ACTIVE_COMPARATOR"},{"label":"003","type":"OTHER"}],"summary":"The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine psychiatric care setting. Aripiprazole will be investigated in a descriptive manner.","primaryOutcome":{"measure":"Mean Relapse Free Period(Risperidone LAI Versus Quetiapine)","timeFrame":"Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Week 104 or earlier)","effectByArm":[{"arm":"Risperidone LAI","deltaMin":607,"sd":11.4},{"arm":"Quetiapine","deltaMin":533,"sd":15.6}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":96,"countries":["Austria","Bulgaria","Croatia","Czechia","Denmark","Estonia","France","Germany","Greece","Hungary","Ireland","Israel","Latvia","Lithuania","Poland","Portugal","Romania","Saudi Arabia","Slovakia","Slovenia","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=46&filename=CR002269_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":63,"n":329},"commonTop":["Insomnia","Anxiety","Hyperprolactinaemia","Weight increased","Somnolence"]}}